However, no association between capecitabine efficacy and TYMS polymorphic variants has been reported so far [64, 69] and, as for MTHFR, no specific indications have been formulated thus far for the clinical testing of TYMS SNPs in cancer patients who may benefit of fluoropyrimidine treatment. This evidence concerns the gene TYMS and cancer.